Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients

[1] Sterner RC(2021)CAR-T cell therapy: current limitations and potential strategies Blood Cancer J 11 69-161

[2] Sterner RM(2021)Recent advances and discoveries in the mechanisms and functions of CAR T cells Nat Rev Cancer 21 145-226

[3] Larson RC(2017)CAR T-cells for cancer therapy Biotechnol Genet Eng Rev 33 190-e265

[4] Maus MV(2021)CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions Am Soc Clin Oncol Educ Book 41 e246-2332

[5] Muhammad N(2020)Development of CAR-T cell therapies for multiple myeloma Leukemia 34 2317-1758

[6] Mao Q(2021)Transformed lymphoma is associated with a favorable response to CAR-T-Cell treatment in DLBCL patients Cancers (Basel) 13 6073-1005

[7] Xia H(2022)In CAR T cell-treated lymphomas, the T cell rich get richer Nat Med 28 1757-716

[8] Gill S(2020)B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Leukemia 34 985-877

[9] Brudno JN(2021)Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma N Engl J Med 384 705-1014

[10] Gagelmann N(2021)Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy Mediterr J Hematol Infect Dis 13 e2021012-e346

[1] Sterner RC(2021)CAR-T cell therapy: current limitations and potential strategies Blood Cancer J 11 69-161

[2] Sterner RM(2021)Recent advances and discoveries in the mechanisms and functions of CAR T cells Nat Rev Cancer 21 145-226

[3] Larson RC(2017)CAR T-cells for cancer therapy Biotechnol Genet Eng Rev 33 190-e265

[4] Maus MV(2021)CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions Am Soc Clin Oncol Educ Book 41 e246-2332

[5] Muhammad N(2020)Development of CAR-T cell therapies for multiple myeloma Leukemia 34 2317-1758

[6] Mao Q(2021)Transformed lymphoma is associated with a favorable response to CAR-T-Cell treatment in DLBCL patients Cancers (Basel) 13 6073-1005

[7] Xia H(2022)In CAR T cell-treated lymphomas, the T cell rich get richer Nat Med 28 1757-716

[8] Gill S(2020)B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Leukemia 34 985-877

[9] Brudno JN(2021)Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma N Engl J Med 384 705-1014

[10] Gagelmann N(2021)Real-World Outcome in the pre-CAR-T Era of Myeloma Patients Qualifying for CAR-T Cell Therapy Mediterr J Hematol Infect Dis 13 e2021012-e346